Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma

Lancet Oncol. 2007 Feb;8(2):177-8. doi: 10.1016/S1470-2045(07)70037-2.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Hemolytic-Uremic Syndrome / chemically induced*
  • Humans
  • Hypertension / chemically induced
  • Kidney Neoplasms / drug therapy
  • Kidney Neoplasms / pathology
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Male
  • Thrombosis / chemically induced*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab